SGLT-2 inhibitors for the treatment of HF complicated by T2DM significantly reduce the occurrence of adverse reactions, such as infections, fractures, diabetic ketoacidosis, hyperkalemia, and liver dysfunction, indicating a high level of safety.[55,56] The long-term use of SGLT-2 inhibitors exhibits good tolerability and a low rate of adverse reactions, allowing patients to adhere to treatment with greater peace of mind. The gene discussed is SLC5A2; the disease is hydrops fetalis.